直肠癌术前放化疗后环周切缘对复发与生存的连续影响:多中心回顾性分析
该多中心回顾性分析纳入1476例cT3-4N0-2M0直肠癌患者,均接受50.4 Gy/28次术前放化疗后行全直肠系膜切除术。结果显示环周切缘(CRM)≤1 mm者5年无复发生存率最低(46.2%),CRM 1.1–5 mm者居中(68.6%),CRM>5 mm者最高(77.5%,P<.001);远端切缘≤5 mm与>5 mm在局部复发和远处转移上无显著差异。
要点
- CRM≤1 mm为高危组,5年RFS仅46.2%,局部复发和远处转移均显著升高。
- CRM 1.1–5 mm为中等风险组,远处转移显著增加但局部复发无显著差异。
- 远端切缘≤5 mm与>5 mm在局部复发(P=.310)和远处转移(P=.926)上无显著差异。
核心结论
- CRM≤1 mm的直肠癌患者为高危组,无复发生存率最低。
- CRM 1.1–5 mm患者可能为中等风险组,远处复发中度增加。
- 新辅助放化疗及全直肠系膜切除后,远端切缘与无复发生存无显著关联。
研究设计与样本
- 多中心回顾性分析,纳入1476例cT3-4N0-2M0直肠癌患者。
- 所有患者接受50.4 Gy/28次放疗,同步5-氟尿嘧啶或卡培他滨化疗。
- 放疗后4–8周行全直肠系膜切除术。
主要发现
- 5年无复发生存率在CRM≤1 mm、1.1–5 mm、>5 mm三组间差异显著(46.2% vs 68.6% vs 77.5%,P<.001)。
- CRM≤1 mm组5年局部区域复发累积发生率显著高于其他两组(P<.001)。
- CRM≤1 mm组5年远处转移累积发生率显著高于其他两组(P<.001)。
- CRM 1.1–5 mm组远处转移累积发生率显著高于CRM>5 mm组(P<.001),但局部区域复发无显著差异(P=.192)。
- 远端切缘≤5 mm与>5 mm在局部区域复发(P=.310)和远处转移(P=.926)累积发生率上无显著差异。
关键数值与推荐
- CRM分组标准:≤1 mm、1.1–5 mm、>5 mm。
- 远端切缘分组标准:≤5 mm与>5 mm。
- 放疗剂量50.4 Gy/28次,同步5-氟尿嘧啶或卡培他滨。
- 手术时机为放疗后4–8周。
临床怎么用
- 术后病理报告应明确CRM测量值,按≤1 mm、1.1–5 mm、>5 mm分层评估风险。
- CRM≤1 mm患者属高危,需重点考虑辅助治疗强化和密切随访。
- CRM 1.1–5 mm患者应关注远处转移风险,可能需要相应监测策略。
- 远端切缘≤5 mm不作为独立的不良预后指标用于分层。
局限性
- 本文为回顾性分析,可能存在选择偏倚和混杂因素。
- 摘要未报告随访时长、具体辅助治疗细节及多因素校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To elucidate the proper length and prognostic value of resection margins in rectal cancer patients who received preoperative chemoradiotherapy (CRT) followed by curative total mesorectal excision (TME). METHODS AND MATERIALS: A total of 1476 rectal cancer patients staging cT3-4N0-2M0 were analyzed. All patients received radiation dose of 50.4 Gy in 28 fractions with concurrent 5-fluorouracil or capecitabine. Total mesorectal excision was performed 4 to 8 weeks after radiation therapy. RESULTS: The recurrence-free survival (RFS) at 5 years showed a significant difference between 3 groups: patients with circumferential resection margin (CRM) ≤1 mm, CRM 1.1 to 5 mm, and CRM >5 mm (46.2% vs 68.6% vs 77.5%, P<.001). Patients with CRM ≤1 mm showed a significantly higher cumulative incidence of locoregional recurrence (P<.001) and distant metastasis (P<.001) at 5 years compared with the other 2 groups. Patients with CRM 1.1 to 5 mm showed a significantly higher cumulative incidence of distant metastasis (P<.001), but not locoregional recurrence (P=.192), compared with those with CRM >5 mm. Distal resection margin (≤5 vs >5 mm) did not show any significant difference in cumulative incidence of locoregional recurrence (P=.310) and distant metastasis (P=.926). CONCLUSION: Rectal cancer patients with CRM ≤1 mm are a high-risk group, with the lowest RFS. Patients with CRM 1.1 to 5 mm may be at intermediate risk, with moderately increased distant recurrence. Distal resection margin was not significantly associated with RFS in rectal cancer after neoadjuvant CRT and total mesorectal excision.
引用
- Sung S, Kim SH, Lee JH, et al. Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581407. doi:10.1016/j.ijrobp.2017.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。